Maximilian Kloft

M.D., Clinical research physician @IKF, Frankfurt
PhD student @Pathology Dept. Maastricht. Interest in Immuno-oncology.

[ESMO - Eur. Oncology @myESMO]

How does biology drive treatment decisions in oncology? Join the #YO4YO HowTo Virtual Session to explore the role of pathology in clinical practice with David Rimm and Heike Grabsch, @mkmoutafi & @MaximilianKloft
#ESMOYOC
📅 14 Sept 2026, 15:00-16:00 CEST
🔗 https://t.co/9mPjuZyUty

[ESMO - Eur. Oncology @myESMO]

Are you interested in #TumorAgnostic therapy? Join the #YO4YO session with @BenWestphalen, Ana Tecic Vuger and @mkmoutafi.
📅 7 July 2026 15:00-16:00 CEST
🔗 https://t.co/FqnGKJlaQj

[Maximilian Kloft @MaximilianKloft]

AI-powered tools are rapidly emerging across cancer research and clinical practice.

Looking forward to our discussion on
"How to Evaluate and Collaborate on AI-Powered Tools in Oncology" at the ESMO #YO4YO session.

4 May 15:00 - 16:00 CEST
@myESMO @GuiNaderMarta @Rodrosb

[ESMO - Eur. Oncology @myESMO]

Are you interested in #AI-powered tools in #oncology?
Join the #YO4YO Session w/ @GuiNaderMarta, @MaximilianKloft, @mihaela_aldea & @rdienstmann
📌 How to Evaluate and Collaborate on AI-Powered Tools in Oncology
#ESMOYOC
📅4 May 15:00-16:00 CEST
🔗 https://t.co/UyJIcFrZED

[Maximilian Kloft @MaximilianKloft]

How to proceed from conference abstracts to high-impact publications in #thoraciconcology ? 🔬
Great @myESMO #ELCC2026 mentorship session by #youngoncologists
with wonderful mentors @pompili_cecilia and @DrAlexAdjei, thank you for your insights!

@mkmoutafi
@DrHongchengZhu

[Hongcheng Zhu 祝鸿程 @DrHongchengZhu]

A successful starting #ESMOYOC event of #ELCC26 with Vesalius talk for finding the your niche in thoracic oncology by @stephanieplsaw 🇸🇬 @NReguart 🇪🇸 @BenjaminBesseMD 🇫🇷 @DoctorJSpicer 🇨🇦

Excellent insights deserve #YoungOncologists to learn from our international experts 🤩

[Myrto K. Moutafi @mkmoutafi]

Day 2 of #ELCC26 @myESMO was a blast! 💥
Great insights at the #ESMOYOC Mentorship Session “From trainee to thoracic oncologist: Building your career roadmap” with @peters_solange and @gerryhanna. Thank you 👏
Stay tuned and follow YOCs in the upcoming session!

[Arndt Vogel @ArndtVogel]

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced GC/GEJ cancer
@TheLancetOncol
https://t.co/LicMQtTz6N
🔎 KYM901 phs 1 trial
👉ORR 29%, DCR 68%
👉SAE ��3 68%
👉first CLDN18.2- specific ADC
🧐Phs 3 ongoing...
@myESMO

[Universitätsklinikum Leipzig @UKL_Leipzig]

Am heutigen Holocaust-Gedenktag wie an jedem anderen Tag: #WeRemember. Die Stolpersteine vor unserem Eingang erinnern uns täglich daran, was sich nicht wiederholen darf.

[OncoDaily @oncodaily]

Vivek Subbiah (@VivekSubbiah) shares the Top Phase 1 clinical trial publications of 2024

https://t.co/2knlZHNlk9

#Cancer #ClinicalTrials #Phase1trials #PrecisionOncology #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

[Arndt Vogel @ArndtVogel]

🔥off the press: Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
@ESMO_Open
https://t.co/pPCNjmLMbW
👉🎯💊are effective in BTC
🤨Access to 💊 is a global problem with unacceptable disparities btw countries
🧐We urgently need new approval & reimbursment strategies to provide global access to effective therapies
@myESMO @EASLnews @ILCAnews @curecc #livertwitter

[Annals of Oncology @Annals_Oncology]

Artificial intelligence as a tool to identify predictive biomarker in immuno-oncology:
this systematic review by @PrelajArsela and coll. in Annals of Oncology encompasses genomics, radiomics, pathomics, real-world and multimodal data https://t.co/zsj6XORGQO

[Maximilian Kloft @MaximilianKloft]

Important talk from @sautesfridm about an under-researched topic in oncology. #ESMO23

[Paolo Tarantino @PTarantinoMD]

Historical moment for GU oncology. @tompowles1 brilliantly presents the results of the EV-302 phase 3 trial, showing a doubling of OS for patients with mUC receiving 1L enfortumab vedotin+pembro vs SoC platinum-based chemo. ADCs keep shining and improving outcomes! #ESMO23